ClinicalTrials.gg
RecruitingNCT06138639Updated Jul 8, 2026

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

A Phase 1/2 interventional study of SGT-003 in Duchenne Muscular Dystrophy, sponsored by Solid Biosciences Inc.. Recruiting at 15 sites in 4 countries. Open to male participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Solid Biosciences Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
0 Years to 17 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
49th of 172
60 · median 25
Started
2024
with 14 others
Phase 1/2
25 of 233
3 open now
Primary completion
2027-05
later than 21 of 59 live
Registered
201st of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 49th largest by planned enrollment of the 172 interventional ones that give a count, is one of 15 that started in 2024, is one of 25 in phase 1/2, reaches primary completion later than 21 of the 59 other live ones, and was the 201st registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 0 Years to 17 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participants 4 to \< 7 years of age. Cohort 2 will include participants 7 to \< 12 years of age. Cohort 3 will include participants 0 to \< 4 years of age. Cohort 4 will include participants 12 to \< 18 years of age. Cohort 5 will include participants 10 to \< 18 years of age. Initiation of participant enrollment in Cohorts 4 and 5 will be subject to the accrual of safety and efficacy data from Cohorts 1-3. All participants will receive SGT-003 and will be enrolled in the study for 5 total years for long-term follow up.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • DMD
  • Gene Therapy
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: 4 to \<7 years of age
  • Cohort 2: 7 to \<12 years of age
  • Cohort 3: 0 to \< 4 years of age
  • Cohort 4: 12 to \< 18 years of age
  • Cohort 5: 10 to \< 18 years of age
  • Participant ambulatory status at the time of Screening Part A or Rescreening, as defined by the ability to complete a 10-meter walk/run test in \< 30 seconds:

    • Cohorts 1, 2, and 4: Ambulatory
    • Cohort 3: Either ambulatory or non-ambulatory
    • Cohort 5: Non-ambulatory, but having been previously ambulatory by history
  • Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype confirmed by Sponsor genetic testing. In cases where a genotype may be predictive of residual dystrophin production and/or a clear clinical diagnosis of DMD cannot be made (e.g., due to age), evaluation of dystrophin levels in baseline muscle may be required to determine eligibility under this criterion.
  • Negative for AAV antibodies.
  • regimen:

    • Cohorts 1, 2, 4, and 5: A stable daily oral steroid regimen of at least 0.5 mg/kg/day of prednisone or 0.75 mg/kg/day of deflazacort for ≥12 weeks prior to Screening Part A or Rescreening, allowing for weight-based modifications consistent with clinical practice.
    • Cohort 3: N/A
  • Meet 10-meter walk/run time criteria
  • Meet time to rise from supine criteria
  • Cohort 5: Meet Performance of Upper Limb (PUL) 2.0 criteria
  • Participant has body weight: ≤ 90 kg

Exclusion criteria

Exclusion Criteria:

  • Treatment with dystrophin modifying drugs within 3 months prior to screening.
  • Current or prior treatment with an approved or gene transfer drug.
  • Exposure to certain approved or investigational drugs within 3 months prior to screening or 5 half-lives since last administration, whichever is longer.
  • Established clinical diagnosis of DMD that is associated with any deletion mutation invariant or variant predicted to not express exons 1 to 11 or, exons 42 to 45, or exons 57 to 69, inclusive, in the DMD gene as documented by a genetic report and confirmed by Sponsor genetic testing.

Other inclusion or exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort 1: SGT-003

    All ambulatory participants from age 4 to \< 7 years will receive a single IV infusion of SGT-003 on Day 1.

    Genetic: SGT-003

  • Experimental
    Cohort 2: SGT-003

    All ambulatory participants from age 7 to \< 12 years will receive a single IV infusion of SGT-003 on Day 1.

    Genetic: SGT-003

  • Experimental
    Cohort 3: SGT-003

    All participants from age 0 to \< 4 years will receive a single IV infusion of SGT-003 on Day 1.

    Genetic: SGT-003

  • Experimental
    Cohort 4: SGT-003

    All ambulatory participants from age 12 to \< 18 years will receive a single IV infusion of SGT-003 on Day 1.

    Genetic: SGT-003

  • Experimental
    Cohort 5: SGT-003

    All non-ambulatory participants from age 10 to \< 18 years will receive a single IV infusion of SGT-003 on Day 1.

    Genetic: SGT-003

Interventions

  • GeneticSGT-003

    Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-µD5)

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (AEs)

    Time frame: Day 360

  2. Change from baseline in Microdystrophin Protein Levels

    Microdystrophin expression evaluation in muscle biopsies

    Time frame: Day 90

Secondary outcomes

  1. Change from Baseline of Microdystrophin Tissue Distribution by Immunofluorescence (IF)

    Time frame: Day 90, Day 360

  2. Change from baseline in Microdystrophin Protein Levels

    Microdystrophin expression evaluation in muscle biopsies

    Time frame: Day 360

  3. Change from Baseline in Time to Rise Velocity

    The Time to rise from supine (TTR) (s) will be captured as part of item 12 of the North Star Ambulatory Assessment (NSAA). Assessment of muscle function using a 17-item scale with each item scored from 0 to 2 and a higher score meaning a better outcome. The NSAA total score is defined as the sum of all 17 items, ranging from 0 to 34, with a higher score meaning a better outcome.

    Time frame: Day 360, Day 540

  4. Change from baseline in Stride Velocity 95th Centile (SV95C)

    Assessment of peak ambulatory performance captured by wearable activity monitoring device.

    Time frame: Day 360, Day 540

  5. Change from baseline in 10-meter walk/run velocity

    The 10MWR (s) will be captured as part of item 17 of the NSAA. Assessment of muscle function using a 17-item scale with each item scored from 0 to 2 and a higher score meaning a better outcome. The NSAA total score is defined as the sum of all 17 items, ranging from 0 to 34, with a higher score meaning a better outcome.

    Time frame: Day 360, Day 540

  6. Change from baseline in 4-stair climb velocity

    Time frame: Day 360, Day 540

  7. Change from baseline in North Star Ambulatory Assessment (NSAA) total score

    Assessment of muscle function using a 17-item scale with each item scored from 0 to 2 and a higher score meaning a better outcome. The NSAA total score is defined as the sum of all 17 items, ranging from 0 to 34, with a higher score meaning a better outcome.

    Time frame: Day 360, Day 540

  8. Change from baseline in 6-minute walk test (6MWT) distance

    Time frame: Day 360, Day 540

  9. Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters

    Time frame: Through Day 360 and Day 540

  10. Number of Participants with Clinically Significant Abnormalities in Vital Signs

    Time frame: Through Day 360 and Day 540

  11. Number of Participants with Clinically Significant Abnormalities in Physical Examinations

    Time frame: Through Day 360 and Day 540

  12. Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG) or Echocardiography (ECHO)

    Time frame: Through Day 360 and Day 540

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
May 6, 2024
Primary completionEst.
May 6, 2027
CompletionEst.
May 6, 2031
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06138639
Lead sponsor
Solid Biosciences Inc.
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
May 6, 2024
Primary completion
May 6, 2027 (estimated)
Completion
May 6, 2031 (estimated)
Last update
Jul 8, 2026

Study contacts

Solid Bio Clinical Trials
Contact
clinicaltrials@solidbio.com
617-337-4680
Solid Bio Clinical Trials
study director · Solid Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion